L-NMMA acetate is a nitric oxide synthase inhibitor of all NOS isoforms, like NOS1, NOS2, and NOS3.
CAT No: 10-101-117
CAS No:17035-90-4 (net), 53308-83-1 (acetate)
Synonyms/Alias:Tilarginine Acetate; Targinine Acetate
L-NMMA Acetate, also known as NG-Monomethyl-L-arginine acetate, is a well-characterized biochemical compound classified as a non-selective nitric oxide synthase (NOS) inhibitor. Structurally derived from the amino acid L-arginine, it features a methylated guanidino group that imparts specific inhibitory activity toward NOS enzymes. This property makes L-NMMA Acetate a valuable tool in the study of nitric oxide (NO) signaling pathways, which are central to various physiological and cellular processes. Its precise mechanism of action and established role in modulating NO production underscore its significance in experimental systems exploring vascular biology, immunological responses, and cellular signaling networks.
Nitric Oxide Synthase Inhibition: L-NMMA Acetate is widely utilized in research as a competitive inhibitor of nitric oxide synthase enzymes, including both endothelial and neuronal isoforms. By mimicking the structure of L-arginine, it competes for binding at the active site of NOS, effectively reducing the enzymatic conversion of L-arginine to nitric oxide. This property allows investigators to selectively modulate endogenous NO levels in vitro and in cell-based assays, providing crucial insights into the regulatory roles of NO in cellular communication, vascular tone, and neurotransmission.
Vascular Biology Research: The compound is frequently employed in studies aimed at elucidating the functions of nitric oxide in vascular systems. Its ability to attenuate NO synthesis enables researchers to dissect the molecular mechanisms underlying vasodilation, endothelial function, and blood vessel reactivity. By selectively inhibiting NOS activity, L-NMMA Acetate serves as a reference compound for examining the interplay between NO signaling and vascular smooth muscle dynamics, as well as for modeling endothelial dysfunction in preclinical settings.
Signal Transduction Studies: In cellular and molecular biology, L-NMMA Acetate is instrumental for probing NO-dependent signaling cascades. Nitric oxide acts as a versatile signaling molecule, modulating pathways such as cyclic GMP production, calcium flux, and protein kinase activation. By inhibiting NO synthesis, the compound facilitates the investigation of downstream effectors and secondary messengers, allowing researchers to delineate the broader impact of NO on cellular homeostasis, gene expression, and adaptive responses to environmental stimuli.
Immunological Investigations: L-NMMA Acetate is also applied in immunology to study the involvement of nitric oxide in immune cell function and inflammatory processes. NO is known to influence macrophage activity, cytokine production, and immune cell signaling. By suppressing NOS activity, the compound provides a means to assess the contribution of NO to immune modulation, pathogen defense mechanisms, and the regulation of inflammatory mediators in both primary cell cultures and established cell lines.
Analytical and Method Development: The compound's well-characterized inhibitory profile makes it a reliable standard in analytical assays designed to quantify nitric oxide production or assess NOS activity. L-NMMA Acetate is frequently used as a control or calibration agent in biochemical assays, fluorescence-based detection systems, and chromatographic analyses. Its inclusion in experimental protocols enhances the accuracy and interpretability of data related to NO metabolism, supporting the development of robust methodologies for nitric oxide quantification and NOS enzyme characterization.
Cardiogenic shock complicating acute myocardial infarction (MI) remains a common and lethal disorder despite aggressive use of early revascularization. Systemic inflammation, including expression of inducible nitric oxide synthase (NOS) and generation of excess nitric oxide, is believed to contribute to the pathogenesis and inappropriate vasodilatation of persistent cardiogenic shock. Preliminary, single-center studies suggested a beneficial effect of NOS inhibition on hemodynamics, renal function, and survival in patients with cardiogenic shock.
Alexander, J. H., Reynolds, H. R., Stebbins, A. L., Dzavik, V., Harrington, R. A., Van de Werf, F., & Hochman, J. S. (2007). Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. Jama, 297(15), 1657-1666.
Syncope is sudden transient loss of consciousness and postural tone with spontaneous recovery; the most common form is vasovagal syncope(VVS). We previously demonstrated impaired post-synaptic adrenergic responsiveness in young VVS patientswas reversed by blocking nitric oxide synthase(NOS). We hypothesised that nitric oxide may account for reduced orthostatic tolerance in young recurrent VVS patients.
Stewart, J. M., Sutton, R., Kothari, M. L., Goetz, A. M., Visintainer, P., & Medow, M. S. (2017). Nitric oxide synthase inhibition restores orthostatic tolerance in young vasovagal syncope patients. Heart, heartjnl-2017.
Guidelines recommend β-blockers and renin-angiotensin-aldosterone system blockers to improve long-term survival in hemodynamically stable myocardial infarction patients with a reduced left ventricular ejection fraction. The prevalence and outcomes associated with β and renin-angiotensin-aldosterone system blocker therapy in patients with ongoing cardiogenic shock is unknown.
van Diepen, S., Reynolds, H. R., Stebbins, A., Lopes, R. D., Džavík, V., Ruzyllo, W., ... & Dauerman, H. L. (2014). Incidence and outcomes associated with early heart failure pharmacotherapy in patients with ongoing cardiogenic shock. Critical care medicine, 42(2), 281-288.
1. Emerging applications of nanotechnology for diagnosis and therapy of disease: a review
5. TMEM16F and dynamins control expansive plasma membrane reservoirs
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More